Pacific Biosciences of California (PACB) PT Raised to $13 at Scotiabank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts PACB Hot Sheet
Price: $2.61 -10%
Rating Summary:
9 Buy, 11 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
9 Buy, 11 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Scotiabank analyst Sung Ji Nam raised the price target on Pacific Biosciences of California (NASDAQ: PACB) to $13.00 (from $12.00) while maintaining a Sector Outperform rating.
You May Also Be Interested In
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- Intel (INTC) PT Lowered to $90 at Piper Sandler
- Stryker (SYK) PT Lowered to $325 at Piper Sandler
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
